CD5+ diffuse large B-cell lymphoma: a narrative review

References

• Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood. 2006;107(1):265–276.
   PubMed Web of Science ®Google Scholar
• Matolcsy A, Chadburn A, Knowles DM. De novo CD5-positive and Richter’s syndrome-associated diffuse large B cell lymphomas are genotypically distinct. Am J Pathol. 1995;147(1):207–216.
   PubMed Web of Science ®Google Scholar
• Zhao P, Li L, Zhou S, et al. CD5 expression correlates with inferior survival and enhances the negative effect of p53 overexpression in diffuse large B-cell lymphoma. Hematol Oncol. 2019;37(4):360–367.
   PubMed Web of Science ®Google Scholar
• Ma X-B, Zhong Y-P, Zheng Y, et al. Coexpression of CD5 and CD43 predicts worse prognosis in diffuse large B-cell lymphoma. Cancer Med. 2018;7(9):4284–4295.
   PubMed Web of Science ®Google Scholar
• Nishimura N, Takeuchi K, Asaka R, et al. MYD88 L265P mutation detected by digital PCR as a prognostic factor in patients with diffuse large B-cell lymphoma in rituximab era. Leuk Res. 2020;97:106426.
   PubMed Web of Science ®Google Scholar
• Woźnialis N, Gierej B, Popławska L, et al. A rare CD5-positive subgroup of diffuse large B-cell lymphoma - clinical, morphological and immunophenotypic features in Polish patients. PJP. 2016;3(3):235–243.
   Web of Science ®Google Scholar
• Xu-Monette ZY, Tu M, Jabbar KJ, et al. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget. 2015;6(8):5615–5633.
   PubMedGoogle Scholar
• Kaneko H, Shimura K, Horiike S, et al. Cytogenetic analysis of de novo CD5-positive diffuse large B-cell lymphoma. Asia Pac J Clin Oncol. 2011;7(4):346–350.
   PubMed Web of Science ®Google Scholar
• Lydyard PM, Jewell AP, Jamin C, et al. CD5 B cells and B-cell malignancies. Curr Opin Hematol. 1999;6:30–36.
   PubMedGoogle Scholar
• Xu Y, Sun W, Li F. De novo CD5+ diffuse large B-cell lymphoma: biology, mechanism, and treatment advances. Clin Lymphoma Myeloma Leuk. 2020;20(10):e782–e790.
   PubMed Web of Science ®Google Scholar
• Bikah G, Carey J, Ciallella JR, et al. CD5-mediated negative regulation of antigen receptor-induced growth signals in B-1 B cells. Science. 1996;274(5294):1906–1909.
   PubMed Web of Science ®Google Scholar
• Perez-Villar JJ, Whitney GS, Bowen MA, Hewgill DH, et al. CD5 negatively regulates the T-cell antigen receptor signal transduction pathway: involvement of SH2-containing phosphotyrosine phosphatase SHP-1. Mol Cell Biol. 1999;19(4):2903–2912.
   PubMed Web of Science ®Google Scholar
• Mizuno K, Tagawa Y, Mitomo K, et al. Src homology region 2 (SH2) domain-containing phosphatase-1 dephosphorylates B cell linker protein/SH2 domain leukocyte protein of 65 kDa and selectively regulates c-Jun NH2-terminal kinase activation in B cells. J Immunol. 2000;165(3):1344–1351.
   PubMed Web of Science ®Google Scholar
• Maeda A, Scharenberg AM, Tsukada S, et al. Paired immunoglobulin-like receptor B (PIR-B) inhibits BCR-induced activation of Syk and Btk by SHP-1. Oncogene. 1999;18(14):2291–2297.
   PubMed Web of Science ®Google Scholar
• Kurosaki T, Maeda A, Ishiai M, et al. Regulation of the phospholipase C-γ2 pathway in B cells. Immunol Rev. 2000;176:19–29.
   PubMed Web of Science ®Google Scholar
• Rothstein TL. Signals and susceptibility to programmed death in B cells. Curr Opin Immunol. 1996;8(3):362–371.
   PubMed Web of Science ®Google Scholar
• Gary-Gouy H, Harriague J, Bismuth G, et al. Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production. Blood. 2002;100(13):4537–4543.
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Ray RM, Johnson LR. STAT3-mediated transcription of Bcl-2, Mcl-1 and C-IAP2 prevents apoptosis in polyamine-depleted cells. Biochem J. 2005;392(Pt 2):335–344.
   PubMed Web of Science ®Google Scholar
• Moreno MJ, Bosch R, Dieguez-Gonzalez R, et al. CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival. J Pathol. 2015;235(3):445–455.
   PubMed Web of Science ®Google Scholar
• Huang K, Kiefer C, Kamal A. Novel role for NFAT3 in ERK-mediated regulation of CXCR4. PLoS One. 2014;9(12):e115249.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Nakamura N, Suzuki R, et al. De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients. Haematologica. 2008;93(8):1195–1202.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Seto M, Okamoto M, et al. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood [Internet]. 2002;99(3):815–821.
   Web of Science ®Google Scholar
• Tang H, Zhou H, Wei J, et al. Clinicopathologic significance and therapeutic implication of de novo CD5+ diffuse large B-cell lymphoma. Hematology. 2019;24(1):446–454.
   PubMed Web of Science ®Google Scholar
• Niitsu N, Okamoto M, Tamaru J-I, et al. Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma. Ann Oncol. 2010;21(10):2069–2074.
   PubMed Web of Science ®Google Scholar
• Alinari L, Gru A, Quinion C, et al. De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort. Am J Hematol. 2016;91(4):395–399.
   PubMed Web of Science ®Google Scholar
• Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50(1):74–87.
   PubMed Web of Science ®Google Scholar
• Yatabe Y, Nakamura S, Seto M. Clinicopathologic study of PRAD1/cyclin D1 overexpressing lymphoma with special reference to mantle cell lymphoma. A distinct molecular pathologic entity. Am J Surg Pathol. 1996;20(9):1110–1122.27.
   PubMed Web of Science ®Google Scholar
• Na HY, Choe J-Y, Shin SA, et al. Characteristics of CD5-positive diffuse large B-cell lymphoma among Koreans: High incidence of BCL2 and MYC double-expressors. PLoS One. 2019;14(10):e0224247.
   PubMed Web of Science ®Google Scholar
• Hermine O, Haioun C, Lepage E, et al. Prognostic significance of bcl-2 protein expression in aggressive non- Hodgkin’s lymphoma. Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood. 1996;87(1):265–272.
   PubMed Web of Science ®Google Scholar
• Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood. 1993;81(1):151–157.
   PubMed Web of Science ®Google Scholar
• Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood. 2003;101(11):4279–4284.
   PubMed Web of Science ®Google Scholar
• Li L, Li Y, Que X, et al. Prognostic significances of overexpression MYC and/or BCL2 in R-CHOP-treated diffuse large B-cell lymphoma: a systematic review and meta-analysis. Sci Rep. 2018;8(1):6267.
   PubMed Web of Science ®Google Scholar
• Ennishi D, Takeuchi K, Yokoyama M, et al. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol Off J Eur Soc Med Oncol. 2008;19(11):1921–1926.
   PubMed Web of Science ®Google Scholar
• Tagawa H, Suguro M, Tsuzuki S, et al. Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood. 2005;106(5):1770–1777.
   PubMed Web of Science ®Google Scholar
• Miyazaki K, Yamaguchi M, Imai H, et al. Gene expression profiling of diffuse large B-Cell lymphomas supervised by CD5 expression. Int J Hematol. 2015;102(2):188–194.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937–1947.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282.
   PubMed Web of Science ®Google Scholar
• Katzenberger T, Lohr A, Schwarz S, et al. Genetic analysis of de novo CD5+ diffuse large B-cell lymphomas suggests an origin from a somatically mutated CD5+ progenitor B cell. Blood. 2003;101(2):699–702.
   PubMed Web of Science ®Google Scholar
• Sarkozy C, Traverse-Glehen A, Coiffier B. Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas. Lancet Oncol. 2015;16(15):e555––e567.
   PubMedGoogle Scholar
• Karnan S, Tagawa H, Suzuki R, et al. Analysis of chromosomal imbalances in de novo CD5-positive diffuse large-B-cell lymphoma detected by comparative genomic hybridization. Genes Chromosomes Cancer. 2004;39(1):77–81.
   PubMed Web of Science ®Google Scholar
• Yoshioka T, Miura I, Kume M, et al. Cytogenetic features of de novo CD5-positive diffuse large B-cell lymphoma: chromosome aberrations affecting 8p21 and 11q13 constitute major subgroups with different overall survival. Genes Chromosomes Cancer. 2005;42(2):149–157.
   PubMed Web of Science ®Google Scholar
• Bertrand P, Maingonnat C, Penther D, et al. The costimulatory molecule CD70 is regulated by distinct molecular mechanisms and is associated with overall survival in diffuse large B-cell lymphoma. Genes Chromosomes Cancer. 2013;52(8):764–774.
   PubMed Web of Science ®Google Scholar
• Scholtysik R, Nagel I, Kreuz M, et al. Recurrent deletions of the TNFSF7 and TNFSF9 genes in 19p13.3 in diffuse large B-cell and Burkitt lymphomas. Int J Cancer. 2012;131(5):E830–E835.
   PubMed Web of Science ®Google Scholar
• Tagawa H, Tsuzuki S, Suzuki R, et al. Genome-wide array-based comparative genomic hybridization of diffuse large B-cell lymphoma: comparison between CD5-positive and CD5-negative cases. Cancer Res. 2004;64(17):5948–5955.
   PubMed Web of Science ®Google Scholar
• Taniguchi M, Oka K, Hiasa A, et al. De novo CD5+ diffuse large B-cell lymphomas express VH genes with somatic mutation. Blood. 1998;91(4):1145–1151.
   PubMed Web of Science ®Google Scholar
• Nakamura N, Hashimoto Y, Kuze T, et al. Analysis of the immunoglobulin heavy chain gene variable region of CD5-positive diffuse large B-cell lymphoma. Lab Invest. 1999;79(8):925–933.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Yamaguchi M, Kobayashi K, et al. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma. Cancer. 2017;123(7):1166–1173.
   PubMed Web of Science ®Google Scholar
• Bohers E, Mareschal S, Bouzelfen A, et al. Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma. Genes Chromosomes Cancer. 2014;53(2):144–153.
   PubMed Web of Science ®Google Scholar
• Kim H-Y, Jang M-A, Kim H-J, et al. Clinical impact of CD5 expression in Korean patients with diffuse large B-cell lymphoma. Blood Res. 2017;52(3):193–199.
   PubMed Web of Science ®Google Scholar
• Thakral B, Medeiros LJ, Desai P, et al. Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH. Eur J Haematol. 2017;98(4):415–421.
   PubMed Web of Science ®Google Scholar
• Hyo R, Tomita N, Takeuchi K, et al. The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma. Hematol Oncol. 2010;28(1):27–32.
   PubMed Web of Science ®Google Scholar
• García-Suárez J, Bañas H, Arribas I, et al. Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study. Br J Haematol. 2007;136(2):276–285.
   PubMed Web of Science ®Google Scholar
• Miyazaki K, Asano N, Yamada T, et al. DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 study. haematol. 2020;105(9):2308–2315.
   PubMed Web of Science ®Google Scholar
• Epperla N, Hamadani M, Reljic T, et al. Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B-cell lymphomas in first remission in the rituximab era: a systematic review and meta-analysis. Cancer. 2019;125(24):4417–4425.
   PubMed Web of Science ®Google Scholar
• Miyazaki K, Yamaguchi M, Suzuki R, et al. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol off J Eur Soc Med Oncol. 2011;22(7):1601–1607.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Zeynalova S, Nickelsen M, et al. CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2016;34(26):3150–3156.
   PubMed Web of Science ®Google Scholar
• Miyazaki K, Asano N, Yamada T, et al. DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study. Haematologica. 2020;105(9):2308–2315.
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, Hong F, Scott DW, et al. Addition of lenalidomide to R-CHOP improves outcomes in newly diagnosed diffuse large B-cell lymphoma in a randomized phase II US Intergroup Study ECOG-ACRIN E1412. J Clin Oncol. 2021;39(12):1329–1338.
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, LaPlant B, Macon WR, et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non–germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. J Clin Oncol. 2015;33(3):251–257.
   PubMed Web of Science ®Google Scholar
• Zhang L-H, Kosek J, Wang M, et al. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Br J Haematol. 2013;160(4):487–502.
   PubMed Web of Science ®Google Scholar
• Goy A, Ramchandren R, Ghosh N, et al. Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL. Blood. 2019;134(13):1024–1036.
   PubMed Web of Science ®Google Scholar
• Sauter CS, Matasar MJ, Schoder H, Devlin SM, et al. A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL. Blood. 2018;131(16):1805–1808.
   PubMed Web of Science ®Google Scholar
• Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922–926.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Feugier P, Flinn IW, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood. 2021;137(5):600–609.
   PubMed Web of Science ®Google Scholar